RaySearch Laboratories AB (publ)
RSLBF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.23 | -1.83 | -6.62 | 0.93 |
| FCF Yield | -0.70% | 0.17% | 1.10% | 0.58% |
| EV / EBITDA | 100.86 | 285.01 | 102.73 | 98.52 |
| Quality | ||||
| ROIC | 4.98% | 2.02% | 4.01% | 3.89% |
| Gross Margin | 96.45% | 90.85% | 92.02% | 92.32% |
| Cash Conversion Ratio | -0.13 | 1.78 | 2.07 | 1.33 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.38% | 9.85% | 13.52% | 12.21% |
| Free Cash Flow Growth | -451.05% | -78.99% | 101.48% | 87.58% |
| Safety | ||||
| Net Debt / EBITDA | 0.99 | 0.75 | -0.72 | 0.12 |
| Interest Coverage | 0.00 | 0.00 | 19.65 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.46 | 0.78 | 2.48 | 2.33 |
| Cash Conversion Cycle | 70.79 | 151.63 | 94.95 | 26.92 |